Response of varicella zoster virus and herpes zoster to silver sulfadiazine.
The addition of silver sulfadiazine to cultures of varicella zoster virus resulted in inactivation of the viral infectivity. At a concentration of 10 micrograms/ml or higher the virus was inactivated after thirty minutes exposure at 37 degrees C. Forty-two patients with herpes zoster were treated topically with 1 percent silver sulfadiazine cream applied four times a day. All patients experienced complete drying of vesicles, marked reduction erythema and edema, and striking elimination of pain and burning sensation within twenty-four to seventy-two hours. The sooner the treatment began after the onset of symptoms, the more dramatic was the response. Postherpetic neuralgia was either mild or did not occur. Signs of local, systemic, or laboratory-documented toxicity were not observed.
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D002478:Cells, Cultured; D005260:Female; D005347:Fibroblasts / Q000382:microbiology; D006562:Herpes Zoster / Q000188:drug therapy*; D014645:Herpesvirus 3, Human / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012837:Silver Sulfadiazine / Q000008:administration & dosage / Q000494:pharmacology*; D013411:Sulfadiazine / Q000494:pharmacology*
D013411:Sulfadiazine; D012837:Silver Sulfadiazine